SeeTreat to Launch ART.1 to Support Adaptive Radiotherapy at ASTRO 2025
Michelle Joiner 7:20pm 30/04/2025 Source: Cision PRwebSeeTreat will demonstrate its first clinical product, ART.1, at Booth 2239 during ASTRO 2025 in San Francisco. ART.1 is a software as a medical device that delivers objective, evidence-based decision support for adaptive treatment re-planning in patients undergoing radiotherapy.
ART.1 automatically calculates delivered dose and propagates daily contours based on each patient's volumetric imaging, while displaying and reporting key clinical metrics. Running silently in the background, ART.1 prioritises only the patient cases needing attention—allowing clinical teams to focus their time where it matters most. The software adds efficient, adaptive-quality treatment capabilities on any standard linear accelerator—without hardware upgrades or workflow disruption.
"Adaptive radiotherapy has traditionally been complex, costly, and limited to well-resourced centers," said Trang Nguyen, CEO and founder of SeeTreat. "We designed ART.1 to perform background analysis of every fraction, prioritising major deviation, and give the clinical team a second set of eyes—without adding to the workload, resources or time."
What Makes ART.1 Different: Saving Days, Not Hours
ART.1 integrates seamlessly with existing linear accelerators and treatment planning systems, and automates the most resource-intensive steps in the adaptive workflow:
- Analyses every structure for every fraction using synthetic CTs, daily dose calculation, and deformable contour propagation
- Sends alerts based on protocol thresholds for dosimetric and volumetric changes to treatment volumes and organs at risk
- Prioritises patients for review—reducing unnecessary checks and freeing up staff
- Minimises manual work by automating and prioritising your adaptive workload
With detection, analysis, and alerts built into a single workflow, ART.1 reduces time to inform a decision from days to minutes—empowering the clinical team to act faster, with greater confidence.
Purpose-Built for Adaptive Radiotherapy
ART.1 was built from the ground up to support daily adaptive evaluation—without new hardware, major IT demands, or added staffing. Its software-only model fits into existing infrastructure, making it ideal for regional and community cancer centers where resources are tight but precision matters.
"We designed ART.1 to perform background analysis of every fraction, prioritising major deviation, and give the clinical team a second set of eyes—without adding to the radiotherapy workload, resources or time."- Trang Nguyen, CEO and founder of SeeTreat.
SeeTreat at ASTRO 2025
Attendees can see ART.1 in action and meet the team behind it at Booth 2239. To schedule a 1:1 demonstration, visit us at Booth 2239!
ART.1 is available for clinical use in Great Britain. ART.1 is available for Research Use Only (RUO) everywhere else. CE Mark and FDA 510(k) pending.
About SeeTreat
SeeTreat is an Australian medical technology company focused on making adaptive radiotherapy safer, faster, and more accessible. Founded in 2023 by Dr. Trang Nguyen and Prof. Paul Keall, SeeTreat enables equitable access to precision cancer treatment, potentially reducing the burden of cancer worldwide. The company builds intelligent software that automates the most difficult parts of the adaptive workflow— helping more clinics deliver adaptive-quality care, every day.
